Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Ocular Pain-Pipeline Review, H2 2016

Ocular Pain-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Ocular Pain-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Ocular Pain-Pipeline Review, H2 2016', provides an overview of the Ocular Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ocular Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ocular Pain

The report reviews pipeline therapeutics for Ocular Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ocular Pain therapeutics and enlists all their major and minor projects

The report assesses Ocular Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ocular Pain

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ocular Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Ocular Pain Overview 7

Therapeutics Development 8

Pipeline Products for Ocular Pain-Overview 8

Ocular Pain-Therapeutics under Development by Companies 9

Ocular Pain-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Ocular Pain-Products under Development by Companies 13

Ocular Pain-Companies Involved in Therapeutics Development 14

D. Western Therapeutics Institute, Inc. 14

InSite Vision Incorporated 15

Kala Pharmaceuticals, Inc. 16

Ocular Therapeutix, Inc. 17

Reata Pharmaceuticals, Inc. 18

Sylentis S.A.U. 19

Valeant Pharmaceuticals International, Inc. 20

Ocular Pain-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Combination Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

(bromfenac sodium + dexamethasone acetate)-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

bromfenac sodium-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

dexamethasone acetate SR-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Drug for Ocular Pain-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ISV-705-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

ketorolac tromethamine-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

loteprednol etabonate-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

loteprednol etabonate next generation-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

NT-71-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

NT-72-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

omaveloxolone-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

RX-10045-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

SYL-1001-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Ocular Pain-Dormant Projects 59

Ocular Pain-Product Development Milestones 60

Featured News & Press Releases 60

Apr 09, 2016: Sun Pharma Receives USFDA Approval For BromSite 60

Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome 60

Sep 02, 2015: InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit 61

Aug 17, 2015: InSite Vision Announces FDA Acceptance of NDA Filing for BromSite 61

Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 62

May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 62

Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite 63

Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 63

Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 64

Nov 29, 2012: InSite Vision Completes Patient Enrollment In Phase III Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 64

Jul 31, 2012: InSite Vision Initiates First Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 65

Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery 66

Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling 67

Dec 15, 2009: InSite Vision To Advance New Ocular Anti-Inflammatory Candidate 68

Appendix 69

Methodology 69

Coverage 69

Secondary Research 69

Primary Research 69

Expert Panel Validation 69

Contact Us 69

Disclaimer 70

List of Figures

Number of Products under Development for Ocular Pain, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Targets, H2 2016 23

Number of Products by Stage and Targets, H2 2016 23

Number of Products by Mechanism of Actions, H2 2016 25

Number of Products by Stage and Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 27

Number of Products by Molecule Types, H2 2016 29

Number of Products by Stage and Molecule Types, H2 2016 29

List of Tables

Number of Products under Development for Ocular Pain, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Ocular Pain-Pipeline by D. Western Therapeutics Institute, Inc., H2 2016 14

Ocular Pain-Pipeline by InSite Vision Incorporated, H2 2016 15

Ocular Pain-Pipeline by Kala Pharmaceuticals, Inc., H2 2016 16

Ocular Pain-Pipeline by Ocular Therapeutix, Inc., H2 2016 17

Ocular Pain-Pipeline by Reata Pharmaceuticals, Inc., H2 2016 18

Ocular Pain-Pipeline by Sylentis S.A.U., H2 2016 19

Ocular Pain-Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 20

Assessment by Monotherapy Products, H2 2016 21

Assessment by Combination Products, H2 2016 22

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 30

Ocular Pain-Dormant Projects, H2 2016 59

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

D. Western Therapeutics Institute, Inc.

InSite Vision Incorporated

Kala Pharmaceuticals, Inc.

Ocular Therapeutix, Inc.

Reata Pharmaceuticals, Inc.

Sylentis S.A.U.

Ocular Pain Therapeutic Products under Development, Key Players in Ocular Pain Therapeutics, Ocular Pain Pipeline Overview, Ocular Pain Pipeline, Ocular Pain Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com